OncoMed Pharmaceuticals To Present At BioCentury's NewsMakers In The Biotech Industry Conference

REDWOOD CITY, Calif., Sept. 20, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that it will present at BioCentury's NewsMakers in the Biotech Industry Conference on September 27th at the Millennium Broadway Hotel and Conference Center in New York City at 3:30 p.m. Eastern Time (12:30 p.m. Pacific Time).

Paul J. Hastings, Chairman and Chief Executive Officer of OncoMed, will provide a company overview. To access the live webcast, and subsequent archived recording, please visit OncoMed's website using the INVESTORS/EVENTS tab or access the webcast at http://www.visualwebcaster.com/event.asp?id=95785 .

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells. OncoMed has five anti-cancer product candidates in clinical development, including demcizumab (Anti-DLL4, OMP-21M18), OMP-59R5 (Anti-Notch2/3), OMP-52M51 (Anti-Notch1), vantictumab (Anti-Fzd7, OMP-18R5), and OMP-54F28 (Fzd8-Fc), which target key cancer stem cell signaling pathways including Notch and Wnt. OncoMed has two other antibodies in preclinical development with Investigational New Drug filings planned for as early as 2014. OncoMed is also pursuing discovery of additional novel anti-CSC product candidates. OncoMed has formed strategic alliances with Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website: www.oncomed.com .
CONTACT: Investor Contact:         OncoMed Pharmaceuticals         Shari Annes         Investor Relations         (650) 888-0902         shari.annes@oncomed.com                  Media Inquiries:         BCC Partners         Karen L. Bergman or         Michelle Corral         (650) 575-1509 or (415) 794-8662         kbergman@bccpartners.com or         mcorral@bccpartners.com

OncoMed Pharmaceuticals, Inc. Logo

If you liked this article you might like

Biotech Movers: Horizon, OncoMed, Inovio

Wall Street Ends Its Losing Streak As Corporate Earnings Take Focus

Closing Bell: Stocks End Higher As Corporate Earnings Take Focus

Stocks Higher Ahead of Earnings From Netflix, United Airlines

Stocks Higher as Wall Street Focuses on Earnings and Mixed Economic Data